NCT00271505View on ClinicalTrials.gov

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 5, 2005

Primary Completion Date

July 27, 2017

Study Completion Date

July 27, 2017

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Bevacizumab (Avastin)

15 mg/kg intravenously (IV) every 3 weeks

DRUG

Carboplatin

AUC 6 IV every 3 weeks

DRUG

Docetaxel

75 mg/m2 IV every 3 weeks

Trial Locations (2)

77030

Lyndon Baines Johnson General Hospital, Houston

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER